Market Closed -
Euronext Paris
11:35:09 2024-04-26 EDT
|
5-day change
|
1st Jan Change
|
14.82
EUR
|
+0.54%
|
|
+4.66%
|
+50.92%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
265.2
|
475.9
|
467.2
|
103.7
|
615.2
|
932.4
|
-
|
-
|
Enterprise Value (EV)
1 |
276.6
|
446.6
|
406.5
|
76.71
|
439.9
|
845
|
887.8
|
657.5
|
P/E ratio
|
-8.98
x
|
-13.1
x
|
-11.6
x
|
-1.97
x
|
-2.86
x
|
-5.79
x
|
-5.46
x
|
-
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
280
x
|
48.2
x
|
1,037
x
|
134
x
|
356
x
|
441
x
|
82.2
x
|
EV / Revenue
|
-
|
263
x
|
41.9
x
|
767
x
|
95.6
x
|
322
x
|
420
x
|
57.9
x
|
EV / EBITDA
|
-8.33
x
|
-11.8
x
|
-9.59
x
|
-1.36
x
|
-3.47
x
|
-5.72
x
|
-5.31
x
|
-3.52
x
|
EV / FCF
|
-9.74
x
|
-14.5
x
|
-8.59
x
|
-1.16
x
|
-4.52
x
|
-6.05
x
|
-5.69
x
|
-4.52
x
|
FCF Yield
|
-10.3%
|
-6.88%
|
-11.6%
|
-85.9%
|
-22.1%
|
-16.5%
|
-17.6%
|
-22.1%
|
Price to Book
|
-
|
-
|
13.4
x
|
15.8
x
|
3.15
x
|
9.2
x
|
-15
x
|
-
|
Nbr of stocks (in thousands)
|
11,762
|
13,834
|
16,363
|
16,774
|
62,646
|
62,918
|
-
|
-
|
Reference price
2 |
22.55
|
34.40
|
28.55
|
6.180
|
9.820
|
14.82
|
14.82
|
14.82
|
Announcement Date
|
20-03-16
|
21-03-31
|
22-03-16
|
23-04-19
|
24-04-02
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
1.7
|
9.7
|
0.1
|
4.6
|
2.622
|
2.115
|
11.35
|
EBITDA
1 |
-33.22
|
-37.94
|
-42.4
|
-56.57
|
-126.7
|
-147.7
|
-167.3
|
-186.7
|
EBIT
1 |
-33.3
|
-38
|
-42.6
|
-56.6
|
-127.4
|
-149.2
|
-168.6
|
-188.7
|
Operating Margin
|
-
|
-2,235.29%
|
-439.18%
|
-56,600%
|
-2,769.57%
|
-5,689.67%
|
-7,970.44%
|
-1,662.88%
|
Earnings before Tax (EBT)
1 |
-34.9
|
-40.1
|
-45.6
|
-74.32
|
-147.7
|
-141.8
|
-159.2
|
-143.8
|
Net income
1 |
-30.6
|
-37.6
|
-41.4
|
-69.8
|
-147.4
|
-159.7
|
-164.8
|
-205.5
|
Net margin
|
-
|
-2,211.76%
|
-426.8%
|
-69,800%
|
-3,204.35%
|
-6,093.02%
|
-7,790.87%
|
-1,810.9%
|
EPS
2 |
-2.510
|
-2.620
|
-2.470
|
-3.130
|
-3.430
|
-2.560
|
-2.715
|
-
|
Free Cash Flow
1 |
-28.41
|
-30.72
|
-47.3
|
-65.88
|
-97.4
|
-139.7
|
-156
|
-145.6
|
FCF margin
|
-
|
-1,807.12%
|
-487.62%
|
-65,885%
|
-2,117.28%
|
-5,327.89%
|
-7,374.18%
|
-1,282.99%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
20-03-16
|
21-03-31
|
22-03-16
|
23-04-19
|
24-04-02
|
-
|
-
|
-
|
Fiscal Period: December |
2022 S1
|
2023 S1
|
2023 S2
|
2024 S1
|
2024 S2
|
---|
Net sales
1 |
-
|
-
|
2.4
|
2.3
|
2.3
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
EBIT
|
-18.6
|
-
|
-
|
-
|
-
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
-
|
Net income
1 |
-29.6
|
-51.95
|
-95.4
|
-93.3
|
-101.6
|
Net margin
|
-
|
-
|
-3,975%
|
-4,056.52%
|
-4,417.39%
|
EPS
|
-
|
-1.450
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
22-09-15
|
23-09-29
|
24-04-02
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
11.4
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
29.3
|
60.7
|
27
|
175
|
87.4
|
44.7
|
275
|
Leverage (Debt/EBITDA)
|
-0.3432
x
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-28.4
|
-30.7
|
-47.3
|
-65.9
|
-97.4
|
-140
|
-156
|
-146
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-145%
|
-131%
|
-202%
|
-122%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
-
|
-
|
2.130
|
0.3900
|
3.120
|
1.610
|
-0.9900
|
-
|
Cash Flow per Share
2 |
-2.400
|
-2.170
|
-2.820
|
-2.940
|
-
|
-2.200
|
-2.100
|
-
|
Capex
1 |
0.94
|
0.9
|
1.64
|
0.31
|
-
|
2.1
|
2
|
6
|
Capex / Sales
|
-
|
52.82%
|
16.93%
|
306%
|
-
|
80.1%
|
94.57%
|
52.87%
|
Announcement Date
|
20-03-16
|
21-03-31
|
22-03-16
|
23-04-19
|
24-04-02
|
-
|
-
|
-
|
Last Close Price
14.82
EUR Average target price
35.74
EUR Spread / Average Target +141.16% Consensus |
1st Jan change
|
Capi.
|
---|
| +50.92% | 995M | | +1.51% | 42.75B | | +49.22% | 41.61B | | +8.57% | 41.34B | | -12.36% | 26.59B | | +8.92% | 25.49B | | -25.13% | 18.12B | | +29.17% | 12.24B | | -3.12% | 11.76B | | +6.35% | 11B |
Other Biotechnology & Medical Research
|